Abstract
We are bringing closer the lecture of professor T. W.
Mak from Canadian Ontario Cancer Institute. The idea of his lecture was - cancer is an illness of metabolism.
Personalized medicine is trying to define genetic mutations (now available about 200,000) and pharmaceutical companies are competing with their inhibitors but this is not the way to the curative treatment, is it? Professor Mak introduced a bit different conception - what is the result of these genetic mutations in general? It is a change in cellular metabolism, generally in all tumour types. And it is mainly 20 fold demand of NADPH and IDH (isocitrate dehydrogenase 1, 2) as the main co-factors of biosynthetic reactions and metabolic transformation).